On May 22, 2025 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, reported the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay (Press release, NeoGenomics Laboratories, MAY 22, 2025, View Source [SID1234653351]). The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour turnaround time.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The c-MET CDx for NSCLC assay detects c-Met protein overexpression, a biomarker observed in up to 50% of patients with advanced NSCLC.¹ It is designed to help identify patients who may be eligible for newly approved targeted therapies, including EMRELIS (telisotuzumab vedotin-tllv), which was recently approved by the U.S. Food and Drug Administration (FDA).*
"Accurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient’s treatment," said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. "The c-MET CDx for NSCLC assay adds an important tool to our testing portfolio, helping oncologists quickly identify patients who may benefit from MET-directed therapies. It also complements our PanTracer suite, enabling comprehensive biomarker profiling for NSCLC."
Key features of NeoGenomics’ assay include:
Companion Diagnostic Indication: Developed in accordance with FDA guidance and validated for use with MET-targeted therapies.
Fast Turnaround: Delivers results within 48 hours to enable timely, informed clinical decisions.
Validated Performance: Designed for use with tumor tissue samples to detect MET protein overexpression.
Integrated NSCLC Offering: Complements NeoGenomics’ broader PanTracer portfolio, including genomic and immuno-oncology markers.
The c-MET CDx for NSCLC assay is now available as part of NeoGenomics’ comprehensive NSCLC testing portfolio. Its addition supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.
For more information or to order the test, visit www.neogenomics.com/cmetcdx.
*EMRELIS (telisotuzumab vedotin-tllv) was approved by the U.S. FDA on May 14, 2025, for adults with previously treated advanced NSCLC with high c-MET protein overexpression.